Research into cancer genomics and transcriptomics is advancing our understanding of cancer development and progression. Genomics approaches for biomarker discovery can lead to the identification and validation of potential diagnostic, predictive, prognostic, and therapeutic cancer biomarkers in the future.
Thermo Fisher Scientific offers a variety of cancer genomics and transcriptomics solutions to help you solve the most urgent challenges in cancer research today:
Extract more information from your FFPE samples with a multi-omic approach by combining somatic mutation and copy number variation profiling, fusion gene analysis, and transcriptome profiling using our NGS, Sanger sequencing, microarray, and qPCR solutions.
Track genomic abnormalities, such as somatic mutations, copy number variations, and fusion genes, even against the background of dynamic tumor heterogeneity in cell-free nucleic acid (cfNA) samples with our targeted NGS and digital PCR assays.
Discover the next-generation of biomarkers to enable better patient stratification with best-in-class tools for the analysis of tumor mutation burden (TMB), T cell receptor (TCR) repertoire, microsatellite instability (MSI), chromothripsis, tumor aneuploidy, and more.
Learn how to maximize funding, save time, save precious samples, and more.
Discover key I‑O research approaches, including checkpoint inhibitor therapy research, CAR T cell therapy research, and cancer vaccine therapy research.
With access to these flexible and proven solutions, you can uncover the genetic variants and RNA signatures you need to power your next cancer research breakthrough.
Accelerate your cancer research with our Oncomine assays and Ion AmpliSeq technology and panels.
The Oncomine cfNA assays and TaqMan Liquid Biopsy dPCR assays together offer a comprehensive set of tools for liquid biopsy applications from broad detection of cancer biomarkers to rapid, precise monitoring of a targeted set of mutations.
Detect chromosomal alterations and somatic mutations that drive cancer as well as germline mutations associated with cancer risk using NGS, Sanger sequencing, microarrays, and qPCR.
Identify epigenetic changes that occur during tumor progression.
Microarrays are the platform of choice for detecting copy number variations (CNVs) such as insertions, deletions, loss-of-heterozygosity (LOH), copy neutral LOH, chromothripsis, and more.
Choose from a variety of RNA expression solutions for fast, simple analysis of coding as well as short and long noncoding RNAs to uncover new RNA-based cancer biomarkers.
Discover new biomarkers for cancer research using exome sequencing, a simple and fast approach for the identification of rare mutations.
Isolate pure populations of cancer cells from tumor tissues for more efficient and accurate results with downstream techniques such as NGS, Sanger sequencing, microarrays, and qPCR.
For Research Use Only. Not for use in diagnostic procedures.
